

ForPatients

by Roche

Multiple Sclerosis (MS)

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Trial Status
Completed

Trial Runs In
2 Countries

Trial Identifier
NCT02545868 2015-001357-32
BN29739

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine [13-PCV], influenza vaccine, keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02545868 2015-001357-32 BN29739
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years & <= 55 Years

Healthy Volunteers
No
